FallberichtOpen Access
When Checkpoint Inhibition Goes Off Target: A Rare Case of Pembrolizumab-Induced Acalculous Cholecystitis
Cureus · 28.05.2026
DOI: 10.7759/cureus.109841 ↗Kurz gefasst
Fallbericht in der Zeitschrift Cureus, erschienen am 28.05.2026. Verfasst von Lan Huynh und 2 weiteren Autor:innen. Beteiligte Einrichtung: Internal Medicine, Wellstar Kennestone Regional Medical Center, Marietta, USA. Die Arbeit nennt 9 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
acalculous cholecystitisadrenal insufficiencyimmune checkpoint inhibitorimmune-related adverse eventpembrolizumab
Autor:innen und Institutionen
- Internal Medicine, Wellstar Kennestone Regional Medical Center, Marietta, USA.
- School of Medicine, Philadelphia College of Osteopathic Medicine - Georgia, Suwanee, USA.
- Hematology and Oncology, Northwest Georgia Oncology Centers Wellstar, Marietta, USA.
Zitieren
APA
Huynh, L., Paulson, S. M., & Shaib, W. (2026). When Checkpoint Inhibition Goes Off Target: A Rare Case of Pembrolizumab-Induced Acalculous Cholecystitis. Cureus. https://doi.org/10.7759/cureus.109841
Vancouver
Huynh L, Paulson SM, Shaib W. When Checkpoint Inhibition Goes Off Target: A Rare Case of Pembrolizumab-Induced Acalculous Cholecystitis. Cureus. 2026. doi:10.7759/cureus.109841
BibTeX
@article{Huynh2026,
author = {Huynh, Lan and Paulson, Stephanie M and Shaib, Walid},
title = {When Checkpoint Inhibition Goes Off Target: A Rare Case of Pembrolizumab-Induced Acalculous Cholecystitis},
journal = {Cureus},
year = {2026},
doi = {10.7759/cureus.109841}
}
EUVIMED